Clearance Summary
NeuroStar Advanced Therapy for adjunctive treatment of OCD, NeuroStar Advanced Therapy System, NeuroStar TMS Therapy System, NeuroStar Advanced Therapy for Mental Health, NeuroStar received FDA 510(k) clearance under submission number K212289, sponsored by Neuronetics, Inc.. The device was reviewed via the Traditional premarket notification pathway and assigned to the Neurology review panel. The statutory decision date of record is 2022-05-06.
- Submission: K212289
- Applicant / Sponsor: Neuronetics, Inc.
- Clearance pathway: Traditional
- Review panel: Neurology
- Device class: Class II
- Regulation citation: 21 CFR 882.5802
- Decision date: 2022-05-06
Classification & Regulation
This clearance is catalogued under FDA product code QCI and 21 CFR 882.5802, within the Neurology review panel as a Class II device.